ChemRar to supply France?s Sanofi with Russian innovation molecules

The ChemRar High-Tech Center, a biotech company outside Moscow, has inked a supply contract with France?s Sanofi for deliveries of ChemRar?s proprietary innovation molecules.

The ChemRar High-Tech Center, a biotech company located in Khimki outside Moscow, announced yesterday that it has inked a supply contract with Sanofi, a French multinational pharmaceutical company, for deliveries of ChemRar?s proprietary innovation molecules to France. The agreement is research-focused and calls for the deliveries of ChemRar?s innovation molecules at early and/or advanced stages of research in such therapeutic areas as oncology, diabetes, cardiovascular diseases, and infectious diseases. The 18-month contract is extendable, ChemRar underscored. According to Irina Ostryakova, the director for communications at Sanofi Eurasia, ?the Russian pharmaceutical market is a priority for Sanofi Group...